RAC-US PDF Dumps 2023 Exam Questions with Practice Test
Dumps for Free RAC-US Practice Exam Questions
The Regulatory Affairs Certification (RAC) is a globally recognized certification for regulatory professionals who work within the healthcare industry. RAC-US is one of the most prestigious certifications in the regulatory affairs field, and it is administered by the Regulatory Affairs Professionals Society (RAPS). The RAC-US certification exam is designed to test the candidate's knowledge of the US regulatory environment and their ability to apply that knowledge to real-world scenarios.
The Regulatory Affairs Certification (RAC) is a globally recognized certification program that aims to assess the knowledge and expertise of regulatory professionals in the pharmaceutical, medical device, and biotechnology industries. The RAC certification program is offered by the Regulatory Affairs Professionals Society (RAPS), which is a leading professional organization for regulatory affairs professionals. The RAC certification program is designed to demonstrate the proficiency of regulatory professionals in understanding and navigating the complex regulatory landscape in the healthcare industry.
NEW QUESTION # 37
Company X acquires Company Y.
Both companies produce pharmaceuticals distributed globally. A regulatory authority requires that all labeling for Company Y's products be converted to Company X within three months. The regulatory affairs professional at
Company X concludes that it is not feasible to meet this request within the time frame.
Which is the FIRST step that the regulatory affairs professional at Company X should take to address the situation?
- A. Develop a plan of action with tasks, timelines, and responsibilities and request an extension period from the regulatory authority.
- B. Convene an urgent meeting with internal stakeholders to inform them of the regulatory authority requirement and assign responsibilities.
- C. Request additional resources from senior management in order to complete the labeling conversion within the time frame given by the regulatory authority.
- D. Submit as many labeling conversion applications as possible within the time frame and request an extension for the remaining ones.
Answer: A
NEW QUESTION # 38
A company is developing a new product for the global market. A new international guideline will recommend relevant studies in the pediatric population, and the guideline will be effective before the approval of the company's new product.
What is the BEST advice the regulatory affairs professional can provide to minimize the impact of this guideline on the successful registration of the new product?
- A. The company should initiate the required pediatric studies immediately to avoid costly delays to the current registration plan.
- B. The new guideline has no impact on the current registration plan since all relevant registration studies are almost completed.
- C. The company should consult with relevant regulatory authorities to determine the potential impact on the current registration plan.
- D. The new guideline has no impact on the current registration plan, but the company must be prepared to defend its decision.
Answer: C
NEW QUESTION # 39
A company is developing a new medical device using innovative technology. Which of the following is MOST critical in working with regulatory authorities?
- A. Frequent communication
- B. Documented agreement
- C. Follow-up meeting after submission
- D. Early collaboration
Answer: A
NEW QUESTION # 40
During an audit of a contract manufacturing facility by a potential client, the auditor requested to be left alone in the records room. The records room contains information on all products produced by the contract manufacturer.
Which action is MOST appropriate for the regulatory affairs professional to take?
- A. Deny the auditor access to the room and records due to confidentiality concerns.
- B. Deny the auditor access to the room and retrieve only the requested records.
- C. Allow the auditor access to the room and records due to the current audit.
- D. Allow the auditor accompanied access to the room to retrieve the records.
Answer: D
NEW QUESTION # 41
Company X has a patent for an anti-inflammatory drug that will expire in one year. In order to minimize the effect of the patent expiration, which is the BEST action for the company to take?
- A. Develop a better brand-name drug in the same class.
- B. Explore litigation strategy for patent infringements on the drug.
- C. Conduct a Phase III study for a new unrelated indication of the drug.
- D. Develop a generic version of the drug.
Answer: D
NEW QUESTION # 42
A materials supplier informs a company that it intends to stop supplying a material critical to the manufacture of the company's products. What action should the company take FIRST?
- A. Qualify another supplier and execute a supplier agreement.
- B. Review the company's existing Quality Management System
- C. Reformulate the products with a replacement material.
- D. Complete a gap analysis to identify options.
Answer: A
NEW QUESTION # 43
Which of the following BEST describes the content of the "Physical, Chemical, and
Pharmaceutical Properties and Formulation" section of an IB?
- A. A review of available data to support the determination of the chemical structure and physical attributes of the drug substance plus batch analysis and stability data for the finished formulation
- B. A detailed summary of the physical and chemical properties of the drug product with a signed expert statement addressing the suitability and stability of the formulation for its intended use
- C. A brief summary of relevant physical, chemical, and pharmaceutical properties:
instructions for storage and handling of the dosage form: and a description of the formulation - D. A description and flow chart illustrating the synthetic route for the active ingredient and the preparation method of the finished product
Answer: C
NEW QUESTION # 44
In addition to protection, what parameters MUST be considered when selecting the primary package (or a product?
- A. Volume and material
- B. Compatibility and safety
- C. Efficacy and material
- D. Safety and efficacy
Answer: B
NEW QUESTION # 45
A company is preparing the submission package for a drug to be registered in international markets. When preparing the legal documentation, which document MUST comply with the
WHO recommendations?
- A. Certificate of Free Sale
- B. Certificate of GMP
- C. Certificate of Analysis for the finished product
- D. Certificate of Pharmaceutical Product
Answer: D
NEW QUESTION # 46
A company receives multiple complaints regarding the text included on a recently launched product's label. What action should the regulatory affairs professional take FIRST?
- A. Notify the regulatory authority.
- B. Recommend an immediate product recall.
- C. Inform the production team.
- D. Compare the approved text with the product label
Answer: D
NEW QUESTION # 47
As a member of the product launch review committee, a regulatory affairs professional discovers a major issue with the labeling of a product prior to production. In addition to informing the committee, which is the BEST approach to address the issue?
- A. Delay the start of product production.
- B. Correct the label text.
- C. Inform the regulatory authorities.
- D. Abort the product launch.
Answer: C
NEW QUESTION # 48
The regulatory authority in Country X issued a request for a mandatory product recall in
Country X due to serious injuries to patients. This product also is distributed in Country Y.
What should the regulatory affairs professional of the product's manufacturer FIRST do in
Country Y?
- A. Prepare the legal team in Country Y for possible litigations.
- B. Review alt distribution records and complaints reported in Country Y.
- C. Initiate a mandatory recall of the product in Country Y.
- D. Draft a formal letter to customers in Country Y about this recall.
Answer: B
NEW QUESTION # 49
According to ICH, which of the following components of study information is NOT required in a clinical study report?
- A. Protocol and protocol amendments
- B. List of lECs or lRBs
- C. Randomization scheme and codes
- D. Detailed CV of all investigators
Answer: D
NEW QUESTION # 50
A company is developing a novel drug to combat AIDS. The preliminary results are very promising and include instances of complete remission. The company has been granted patents in multiple countries for the drug. The regulatory affairs professional is asked to prepare a brief report concerning potential problems for marketing of the product worldwide. Which of the following is the MOST important consideration to discuss?
- A. The stability of the drug in all zone conditions
- B. International import and export regulations
- C. Doha Declaration in the TRIPS Agreement
- D. The time frame in which the patent will expire
Answer: A
NEW QUESTION # 51
Following the introduction of a new regulation, an evaluation of the company's products by the regulatory affairs professional indicates that 60 percent do not comply with the regulation.
What should the regulatory affairs professional do FIRST to meet the new requirement?
- A. Communicate with the relevant internal departments.
- B. Contact the trade association for advice.
- C. Prepare documents for the files.
- D. Request a permanent waiver from the new regulation.
Answer: A
NEW QUESTION # 52
Which of the following is NOT required to be included in a marketing application?
- A. Administrative forms
- B. Evidence of fee payment
- C. Final printed label
- D. Quality, safety, and efficacy Information
Answer: B
NEW QUESTION # 53
A protocol for a pivotal registration trial of a new product is submitted to a major regulatory authority for review and approval. The regulatory authority issues the company a written commitment that if the studies are completed as outlined in the protocol and the results meet the pre-specified criteria for efficacy and safety, the product will be approved.
During the final week of the review of the marketing application, which has fully met all pre- specified criteria, the company receives a letter from the regulatory authority stating that it no longer believes that the product will be approved based on a recent withdrawal of a similar product in another country.
What is the BEST response?
- A. Review the regulatory guidelines to determine how to proceed.
- B. Notify the regulatory authority regarding Its obligation to honor the commitment to approve the application.
- C. Consult with the legal department to discuss the best course of action.
- D. Request a meeting with the regulatory authority to discuss the application.
Answer: D
NEW QUESTION # 54
In preparation for the development of a new line of products, a regulatory affairs professional is asked to prepare a short presentation for senior management. Which of the following topics is MOST important to cover?
- A. Previous actions taken by regulatory authorities on similar products
- B. Capacity of the manufacturing facilities to fully produce the new product
- C. Potential clinical sites for the Phase III clinical trial
- D. Regulatory requirements for labeling and packaging
Answer: A
NEW QUESTION # 55
After submission to the regulatory authority, a substantial error was found in the application. In order to resolve this issue, what should be done FIRST?
- A. Resubmit the entire package.
- B. Contact the legal department and ask them how to proceed.
- C. Inform upper management immediately.
- D. Verify the procedure in the regulation for the corrections.
Answer: D
NEW QUESTION # 56
Which analysis method is MOST appropriate to prioritize risk and monitor the effectiveness of risk control activities for a medical device?
- A. Fault tree analysis
- B. Failure modes, effects, and criticality analysis
- C. Fishbone analysis
- D. Quality by design analysis
Answer: B
NEW QUESTION # 57
Which of the following is an example of an acceptable statement for an advertisement of an approved arthritis medication?
- A. "Product X is effective in all patients with arthritis."
- B. "Product X is a guaranteed cure for arthritis."
- C. "Product X is effective for the treatment of arthritis."
- D. "Product X is safe for arthritis and without side effects."
Answer: C
NEW QUESTION # 58
The safety database for an anti-hypertensive drug consists of the following:
* 461 patients exposed for three months
* 343 patients exposed for six months
* 112 patients exposed for nine months
* 74 patients exposed for 12 months
Overall exposure is 2.000 patients. Which long-term ICH data requirement has NOT been met?
- A. 200 patients for nine months
- B. 100 patients for 12 months
- C. 500 patients for three months
- D. 3.000 total patient exposures
Answer: B
NEW QUESTION # 59
Which of the following is MOST appropriate for the purpose of lot release of biologics?
- A. Inventory control
- B. Quality verification
- C. Safety assurance
- D. Efficacy confirmation
Answer: B
NEW QUESTION # 60
......
The Regulatory Affairs Certification (RAC) US certification exam is a professional certification that is offered to regulatory affairs professionals in the United States. It is designed to assess the knowledge and skills of regulatory professionals in the US who are involved in the development, manufacture, and commercialization of medical devices, pharmaceuticals, and other healthcare products. RAC-US exam covers a range of topics related to regulatory affairs, including regulatory strategy, compliance, quality systems, and legal and ethical issues.
Check your preparation for RAPS RAC-US On-Demand Exam: https://www.dumpsactual.com/RAC-US-actualtests-dumps.html
RAC-US Dumps PDF And Certification Training: https://drive.google.com/open?id=1eKtMHiA50OxkBz0eOHoWXoaOw3sLnqBF
